Companies in #Metabolic disease
Found 3 companies operating in this sector.
Fractyl Health is a metabolic therapeutics company developing disease-modifying treatments for type 2 diabetes and obesity. Its lead platform, the Revita DMR System, is an outpatient endoscopic procedure that uses hydrothermal ablation to resurface the duodenal mucosa and reset the metabolic signalling associated with chronic high-fat, high-sugar diets; the company reported six-month topline results from the 308-patient randomized, double-blind, sham-controlled REMAIN-1 Pivotal Cohort in October 2026, and is pursuing Revita as a weight-maintenance therapy after GLP-1 discontinuation. Its second platform, Rejuva, is an adeno-associated virus-delivered pancreatic gene therapy designed to restore endogenous metabolic hormone function for durable remission of type 2 diabetes and obesity. Founded as Fractyl Laboratories in 2010 and renamed Fractyl Health in June 2021, the company is headquartered in Burlington, Massachusetts and completed its initial public offering on Nasdaq in February 2024 at $15.00 per share.
Chinese biotech developing innovative biologics including monoclonal antibodies and bispecifics for oncology, ophthalmology, and autoimmune diseases.
Clinical-stage biopharmaceutical company developing peripheral CB1 receptor therapies for obesity and metabolic conditions. Recently combined with Redx Pharma into Fibrx Therapeutics to advance a fibrosis-focused pipeline.